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Background: Lung cancer is a leading cause of mortality. The most common cancer subtype, non small cell
lung cancer (NSCLC), accounts for 85-90 % all cases and is mainly caused by environmental and genetic factors.
Mechanisms involved in lung carcinogenesis include deregulation of several kinases and molecular pathways
affecting cell proliferation, apoptosis and differentiation. Despite advances in lung cancer detection, diagnosis
and staging, survival rate still remains poor and novel biomarkers for both diagnosis and therapy need to be
identified. In the present study, we have explored the potential of novel specific biomarkers in the diagnosis of
NSCLC, and the over-expression/activation of several kinases involved in disease development and progression.
Method: Lung tumor tissue specimens and adjacent cancer-free tissues from 8 NSCLC patients undergoing surgery
were collected. The differential activation status of ERK1/2, AKT and IKBα/NF-κβ was analyzed. Subsequently, protein
expression profile of NSCLC vs normal surrounding tissue was compared by a proteomic approach using LC-MS MS.
Subsequently, MS/MS outputs were analyzed by the Protein Discoverer platform for label-free quantitation analysis.
Finally, results were confirmed by western blotting analysis.
Results: This study confirms the involvement of ERK1/2, AKT, IKBα and NF-κβ proteins in NSCLC demonstrating a
significant over-activation of all tested proteins. Furthermore, we found significant differential expression of 20 proteins
(Rsc≥ 1.50 or≤−1.50) of which 7 are under-expressed and 13 over-expressed in NSCLC lung tissues. Finally, we validated,
by western blotting, the two most under-expressed NSCLC tissue proteins, carbonic anhydrase I and II isoforms.
Conclusion: Our data further support the possibility of developing both diagnostic tests and innovative targeted
therapy in NSCLC. In addition to selective inhibitors of ERK1/2, AKT, IKBα and NF-κβ, as therapeutic options, our data, for
the first time, indicates carbonic anhydrase I and II as attractive targets for development of diagnostic tools enabling
selection of patients for a more specific therapy in NSCLC.
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Lung cancer (LC) remains the leading cause of cancer
death worldwide accounting for 14.1 million new cancer
cases and 8.2 million deaths per year [1, 2]. Worldwide inci-
dence appears to be variable but equally distributed with in-
creasing trends among males and females [1, 2]. LC is* Correspondence: aurora.daniele@unina2.it
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(SCLC) and non-small cell lung cancer (NSCLC), the latter
representing 85-90 % of all cases of LC [3]. Response to
current cytotoxic therapies has reached a plateau in terms
of response rate and survival [4, 5]. The development of
molecular profiling technologies to assess DNA, RNA, pro-
teins and metabolites heralds a new era in the understand-
ing of the molecular basis of non-small-cell lung carcinoma
(NSCLC) leading to potential advances in management and
treatment of lung cancer [6]. Novel molecular markers inicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Nigro et al. Respiratory Research  (2015) 16:74 Page 2 of 10non small-cell lung cancer (NSCLC) also include DNA
damage repair genes. The pathogenesis of NSCLC cancer is
complex and influenced by multiple factors including: a)
environment (i.e. exposure to carcinogens, smoking habit,
diet); b) genetic and epigenetic changes (such as p53 and
EGFR gene mutations); c) pulmonary and systemic inflam-
matory conditions (such as concurrent Chronic Obstructive
Pulmonary disease) [7–17]. At cellular level, activation sta-
tus of several kinases involved in cell proliferation, apop-
tosis and inflammation is central to establishment and
development of carcinogenesis. For example, constitutive
activation of MEK-ERK, PI3K-AKT and/or PI3K-AKT-NF-
κβ pathways plays a key role in oncogenesis and strongly
promotes LC invasiveness [13–17]. AKT activation is
present in 51 % of NSCLC although AKT mutations are
rare (<1 %) [18, 19]. However, the role of MEK and PI3K
pathways as prognostic and/or predictive markers for can-
cer remains controversial [20]. Today, the MEK and AKT
inhibitors combined with chemotherapy are very promising
for the treatment of several human cancers, including
NSCLC [18, 19].
Despite the introduction of diagnostic tools such as com-
puted tomography (CT) scans, Positrion Emission Tomog-
raphy (PET) scan and bronchoscopy, the early diagnosis of
LC remains unsatisfactory [20]. Circulating biochemical
biomarkers such as carcinoembryonic antigen (CEA) TPA,
CYFRA 21.1 etc. have a limited impact in early diagnosis
whereas methylation-based assays may represent a more
promising strategy for early detection and follow-up of
NSCLC by means of a differential label-free proteomic ana-
lysis [21]. Actually, cancer detection, diagnosis and staging
may be further improved by molecular selection [2, 21]. As
current early detection procedures and treatments are un-
satisfactory in terms of impact on quality of life and overall
survival novel biomarkers need to be identified. In this con-
text, the emerging “-omics” approach represents an import-
ant tool in the detection and quantitation of novel key-
proteins as putative biomarkers for LC [3, 22].
In this study, we collected lung tumour specimens from
8 NSCLC chemotherapy naive patients undergoing sur-
gery as well as surrounding cancer-free lung tissues and:
a) investigated activation status of ERK, AKT, IKBα and
ΝF-κβ; b) defined novel specific biomarkers for NSCLC
diagnosis by means of a differential label-free proteomic
analysis. We found: a) activation of all tested proteins and
b) 20 proteins differentially expressed between NSCLC
and controls. Finally, we validated, by western blotting,
the two most differentially expressed proteins, carbonic
anhydrase I and II (CAI, CAII) isoforms.
Materials and methods
Lung tissues sampling
NSCLC tumour tissue specimens and surrounding cancer-
free tissue were collected from eight chemotherapy naïvepatients who underwent thoracic surgery. Hystological
analysis of tumour tissue specimens was conducted by pa-
thologists at Monaldi Hospital of Naples and confirmed
the diagnosis as follows: six adenocarcinoma and two ade-
nosquamous carcinoma; surrounding cancer-free lung
specimens showed evidence of airway remodeling and
signs of mucociliary dysfunction and alveolar destruction
consistent with diagnosis of Chronic Obstructive pulmon-
ary diseases. Samples were immediately frozen at −80 °C.
The study was approved by the local ethics committee and
conducted in accordance with ethical principles stated in
most recent version of the Declaration of Helsinki on the
applicable guidelines for good clinical practices.
Protein extraction
Lung tissues were homogenized in buffer containing
50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 % [v/v] Tri-
ton X-100, 10 % [v/v] glycerol, 0.5 mM PMSF and
complete mini protease inhibitor cocktail (Roche, Basel,
Switzerland). Tissues were disrupted using a Dounce
homogenizer and centrifuged at 16,000 g at 4 °C for
30 min. Protein concentrations were determined using
Bradford’s reagent (Biorad Laboratories, CA, USA).
Western blotting analysis
Protein extracts (30 μg) from each of 8 NSCLC and
cancer-free lung tissue were incubated in Laemmli buffer
with DTT, resolved on SDS-PAGE and then transferred
onto nitrocellulose membranes (GE Healthcare, TX, USA)
by Mini trans-blot electrophoresis transfer as previously
described (Bio-Rad Laboratories, CA, USA) [23]. p-ERK1/
2, ERK1/2, p-AMPK, AMPK, p-AKT, AKT, p-P38, P38, p-
IKBα, IKBα antibodies were from Cell Signaling,
Netherlands; NF-κβ antibody was from BD bioscience;
CAI antibody was from Santa Cruz Biotechnology, MA,
USA; CAII antibody was from Rockland, PA, USA;
GAPDH and β-actin antibodies were from Sigma-Aldrich,
MO, USA. Immunoblots were detected using the ECL-
Advance Western Blotting Detection kit (GE Healthcare,
TX, USA). Western blot images were scanned by PDquest
7.1 software (Bio-Rad Laboratories, CA, USA). Densito-
metric measurements were made with the Quantity One
4.5 tool (Bio-Rad Laboratories, CA, USA). Each experi-
ment was performed at least three times in duplicate.
In-gel digestion
Pooled protein extracts (100 μg) were obtained by mix-
ing equal amounts of all 8 NSCLC samples as well as of
corresponding controls. Both pooled protein samples
were re-suspended in Laemmli buffer with 0.1 M DTT,
incubated at 95 °C for 5 min and separated by SDS-
PAGE. Molecular weight was estimated by using
Precision Plus All Blue protein standards (Bio-Rad
Laboratories, CA, USA). Protein electrophoretic patterns
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Protein bands of interest were excised from gel lanes,
crushed and washed first with acetonitrile (ACN) and
then with 50 mM ammonium bicarbonate (AMBIC); en-
zymatic digestions were carried out as previously de-
scribed [24]. In summary, protein samples were reduced
in 10 mM DTT for 45 min at 56 °C and alkylated in
55 mM iodoacetamide in 50 mM AMBIC for 30 min at
RT in the dark. Subsequently, gel particles were washedFig. 1 ERK1/2 and AKT kinases are significantly more activated in NSCLC th
image and graphical representation of pixel quantization of p-ERK1/2 and r
western blotting image and graphical representation of pixel quantization of
was performed three times in duplicate.* = p < 0.05 by t-test analysis. For othewith 50 mM AMBIC and ACN and rehydrated in a
modified trypsin solution (10 ng/μl) (Sigma, MO, USA)
in 50 mM AMBIC pH 8.5, at 4 °C for 2 h. After removal
of enzymatic solution, an aliquot of buffer solution was
added and incubated at 37 °C for 18 h. The supernatant
was collected, while gel pieces were subjected to further
extraction in ACN at 37 °C for 15 min. Peptides ob-
tained from extraction were pooled, vacuum-dried and
resuspended in 0.2 % HCOOH before MS analysis.an in control lung tissues. a One representative western blotting
elative total ERK1/2 of 8 lung tissue specimens. b One representative
p-AKT and relative total AKT of 8 lung tissue specimens. Each experiment
r details see materials and methods
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Peptide mixtures were analyzed by LC-MS MS using the
LC/MSD Trap XCT Ultra (Agilent Technologies, CA,
USA) equipped with a 1100 HPLC system and a chip
cube (Agilent Technologies, CA, USA) as previously de-
scribed [24]. Briefly, after loading, peptide mixture (8 μl
in 0,2 % HCOOH) was pre-concentrated, washed at
4 μl/min in 40 nl enrichment column (Agilent Tech-
nologies chip) and separated on a RP-C18 column
(75 μm × 43 mm) at a flow rate of 200 nl/min with a lin-
ear gradient of eluent B (2 % formic acid in acetonitryl)
in eluent A (2 % formic acid) from 5 to 60 % in 60 min.
Peptides were analyzed using data-dependent acquisition
of MS scan (400–2000 m/z) followed by MS/MS scans
of the three most abundant ions. Dynamic exclusion was
used to acquire a more complete survey of the peptides.
A permanent exclusion list of the most frequent peptide
contaminants was included in the acquisition as previ-
ously described [25].Protein identification and quantitation
MASCOT software (Matrix Science, London, UK) was
used for protein database searching as previously reportedFig. 2 NF − κβ and p-IKBα are significantly more expressed in NSCLC than
and graphical representation of pixel quantization of NF − κβ and relative t
blotting image and graphical representation of pixel quantization of p-IKBα
performed three times in duplicate.* = p < 0.05 by t-test analysis. For other[26]. The searches were performed using the NCBI data-
base and the following standard parameters: Homo
Sapiens; one missed cleavage; carboxyamidomethylation
of Cys, partial Met oxidation and putative modification of
Gln to pyro-Glu, mass tolerance of 300 ppm on precur-
sor ions, and 0.6 Da on the product ions. Individual ion
scores >43 indicate identity or extensive homology (p <
0.05). For label-free quantitation, Mascot format text
files were analyzed by Proteome Discoverer platform
(version 1.3; Thermo Scientific, Bremen, Germany),
interfaced with an in-house Mascot server (version 2.3,
Matrix Science, London, UK). All peptides with FDR ≤
0.01 and a peptide rank of 1 were included. Spectral
counts (SpC) were used for estimating protein abun-
dance and comparing the expression of the same pro-
tein between tumour and control tissues. SpC log Ratio
(Rsc) and Normalized Spectral Abundance Factor
(NSAF) were calculated as previously described [23].Statistical analysis
Data are expressed as means ± SD and median. The statis-
tical significance was established at p <0.05. Two groups
were compared with 2-tailed unpaired Student t-test.in control lung tissues. a One representative western blotting image
otal GAPDH of 8 lung tissue specimens. b One representative western
and total IKBα in 8 lung tissue specimens. Each experiment was
details see materials and methods
Fig. 3 Differential protein expression profile between pooled tumour
and control samples from 8 NSCLS patients (6 with histotype of AC
and 2 with histotype of ASC). Arrow indicates protein band associated
to CAI and CAII isoforms identification. For other details see materials
and methods
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ERK1/2 and AKT kinases are significantly more activated
in NSCLC tissues
To analyze the expression profile of the most relevant
proteins regulating cell survival proliferation and apop-
tosis in NSCLC, we evaluated the activation of MAPK,
ERK1/2 and AKT kinases in LC tissue specimens. We
demonstrated that p-ERK1/2 and p-AKT activation was
statistically different between control cancer-free and
NSCLC tissues; in fact, cancer specimens have a signifi-
cantly higher expression of p-ERK1/2 and p-AKT
compared to the control (p < 0.05) (Fig. 1a, and b, re-
spectively). Ιn particular, p-ERK1/2 over-activation is
1,8 fold and p-AKT over-activation is 1,3-fold higher in
NSCLC than in cancer-free tissues.
NF-κβ and IKBa proteins are over expressed/activated in
NSCLC tissues
We analyzed the expression of NF − κβ and p-IKBα, two
proteins involved in the control of survival and inflam-
mation and therefore potentially affected in cancer spec-
imens. We found that NSCLC tissues have statistically
higher expression of NF − κβ and IKBα compared to
control cancer-free (Fig. 2a, b, respectively). Ιn particular,
NF − κβ is over-expressed 2.2 fold while IKBα is 4-fold
over-expressed in NSCLC respect to cancer-free tissues.
Identification of differentially expressed proteins in
NSCLC tissues
We analyzed the protein expression profile of NSCLC
and control cancer-free tissues in order to search for po-
tentially LC biomarkers. Pooled protein extracts from 8
NSCLC and those from adjacent cancer-free lung tissues
were fractionated onto a 10 % SDS-PAGE. As shown in
Fig. 3, electrophoretic patterns between NSCLC and
control extracts differed mainly in the low MW gel re-
gion. Protein bands from both lanes were excised indi-
vidually, in-gel digested with trypsin, and analyzed by
LC–MS/MS. We identified 38 proteins (see Table 1).
In order to quantitatively compare the protein expres-
sion profiles of NSCLC and cancer-free lung tissues,
MS/MS outputs were analyzed by the Protein Discoverer
platform and submitted to label-free quantitation ana-
lysis. Table 2 contains the details of the label-free quanti-
tation method based on spectral counting for protein
abundance estimation. In addition to the Normalized
Spectral Abundance Factor (NSAF) for each samples, it
has been calculated the semi-quantitative parameter
Rsc, representing the log2 ratio between the protein ex-
pression level of control vs NSCLC lung tissues. This
label-free procedure revealed 20 differentially expressed
proteins with Rsc ≥ 1.50 or ≤ −1.50. In Table 2 such spe-
cies are ranked from the highest Rsc value to the lowest.
In particular, our analysis demonstrated that sevenproteins with Rsc ≥ 1.50 are over-expressed in control,
while 13 proteins Rsc ≤ −1.50 are over-expressed in
NSCLC tissues.
Validation of carbonic anhydrase I and II isoforms
Among proteins identified by MS analysis, we consid-
ered and validated carbonic anhydrase I (CAI) and II
(CAII) isoforms. In fact, the two isoforms were identified
in an intense protein band (MW between 25 kDa and
37 kDa), present in control and almost absent in the
NSCLC (Fig. 3, as indicated by arrow); they were then
quantified by label-free quantitation analysis. This pro-
cedure confirmed the strong over-expression of CAI and
CAII (Rsc = 2,10 and Rsc = 3,10, respectively) in the con-
trol compared to NSCLC tissues (see Table 2). Western
blotting analysis verified the significant under-expression
of CAI and CAII proteins in NSCLC tissues compared
to the control (Fig. 4a, b).
Discussion
Surgical resection, when indicated, remains the best
treatment option for LC patient whilst radiotherapy and
chemotherapy, although effective, have plateaued in
terms of response and survival [18, 19]. This highlights
the necessity for earlier diagnosis and more specific ther-
apies to be found. We focused on NSCLC, the most
common LC subtype, investigating: a) the activation/
Table 1 Identified proteins in control and NSCLC tissues by MS analysis
Protein Gene Gene ID MWa Mascot Scoreb Mascot Scoreb
[Peptide]c [Peptide]c
NSCLC Control
lactoferrin precursor LTF 12083188 80214 946 [15] 298 [5]
transferrin TF 37747855 79310 581 [9] 940 [15]
78 kDa glucose-regulated protein precursor HSPA5 16507237 72402 507 [8] 503 [8]
moesin MSN 4505257 67892 412 [8] 396 [7]
myeloperoxidase, isoform CRA_d MPO 119614879 76923 331 [6] 73 [1]
protein disulfide-isomerase A4 precursor PDIA4 4758304 73229 191 [3] 128 [2]
glyceraldehyde-3-phosphate dehydrogenase GAPDH 31645 36201 581 [9] 375 [6]
annexin A2 isoform 2 ANXA2 18645167 38808 975 [16] 504 [10]
annexin A1 ANXA1 4502101 38918 587 [8] 522 [7]
L-lactate dehydrogenase A isoform 1 LDHA 5031857 36950 391 [7] N. D.d
aldolase A ALDOA 28614 39706 240 [4] 65 [1]
peroxiredoxin-1 PRDX1 4505591 22324 158 [3] 253 [5]
Aldo-keto reductase family 1 member C4 AKR1C4 308153631 37442 155 [3] N. D.d
60S acidic ribosomal protein P0 RPLP0 4506667 34423 133 [2] N. D.d
Actin, beta ACTB 16359158 42078 103 [2] 238 [4]
alcohol dehydrogenase beta subunit ADH1B 178098 40665 N. D.d 107 [2]
cathepsin D CTSD 157879206 26511 151 [3] 131 [2]
stomatin STOM 14715077 31958 112 [2] N. D.d
apolipoprotein A-I, isoform CRA_b APOA1 177827 23454 566 [9] 1057 [17]
ribosomal protein L7 RPL7 1335288 29907 170 [2] 75 [1]
tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein, gamma
YWHAG 380765197 28373 169 [2] 96 [1]
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, beta polypeptide variant
YWHAB 62089104 22563 48 [1] 113 [2]
triosephosphate isomerase 1 TPI1 136066 26894 633 [10] 394 [6]
proteasome subunit alpha type-6 PSMA6 8394076 27838 184 [3] 65 [1]
carbonic anhydrase 1 CA1 4502517 28909 104 [2] 482 [8]
carbonic anhydrase 2 CA2 15080386 29215 N. D.d 237 [4]
azurocidin AZU1 28977 27093 130 [2] N. D.d
phosphoglycerate mutase 1 PGAM1 4505753 28900 91 [2] N. D.d
enoyl-CoA hydratase EHHADH 1922287 31807 107 [2] N. D.d
profilin-1 PFN1 4826898 15216 N. D.d 103 [2]
endoplasmic reticulum protein 29, isoform CRA_b ERP29 119618398 29638 102 [2] N. D.d
pre-serum amyloid P component APCS 337758 25495 337 [5] 318 [5]
peroxiredoxin-6 PRDX6 134254698 25011 342 [6] 299 [5]
MHC class II antigen HLA-DRB1 10185082 30525 N. D.d 183 [3]
MHC class I antigen HLA-DQB 325656872 21947 N. D.d 150 [3]
Rab5c-like protein RAB5C 508285 23781 101 [2] 97 [2]
proteasome subunit beta type-4 PSMB4 22538467 29242 N. D.d 211 [3]
rho GDP-dissociation inhibitor ARHGDIB 56676393 23031 N. D.d 122 [2]
aTheoretical MW
bProtein score assigned by Mascot software is derived from ion scores that are -10*Log [p], where p is the probability that the observed match is a random event
cNumber of peptides matched
dNot determined
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Table 2 Spectral counting and protein ratios for differentially expressed proteins
Protein Gene NSAFa NSAFa Rsc
b
NSCLC Control
carbonic anhydrase 2 CA2 0 0,00693 3,10
MHC class I antigen HLA-DQB 0 0,0131 2,43
alcohol dehydrogenase beta subunit ADH1B 0 0,00356 2,43
carbonic anhydrase 1 CA1 0,00559 0,0180 2,10
profilin-1 PFN1 0 0,00513 1,94
MHC class II antigen HLA-DRB1 0 0,00931 1,94
rho GDP-dissociation inhibitor ARHGDIB 0 0,00393 1,94
aldolase A ALDOA 0,00591 0,000974 -1,61
ribosomal protein L7 RPL7 0,00869 0,00143 -1,61
enoyl-CoA hydratase EHHADH 0,00250 0 -1,97
lactoferrin precursor LTF 0,0124 0,00154 -2,25
proteasome subunit alpha type-6 PSMA6 0,0174 0,00144 -2,52
Aldo-keto reductase family 1 member C4 AKR1C4 0,00579 0 -2,71
stomatin STOM 0,00604 0 -2,71
60S acidic ribosomal protein P0 RPLP0 0,00807 0 -3,20
phosphoglycerate mutase 1 PGAM1 0,0107 0 -3,20
endoplasmic reticulum protein 29, isoform CRA_b ERP29 0,00894 0 -3,20
myeloperoxidase, isoform CRA_d MPO 0,0184 0,00076 -3,48
L-lactate dehydrogenase A isoform 1 LDHA 0,00859 0 -3,57
azurocidin AZU1 0,0161 0 -3,86
aNormalized Spectral Abundance Factor
bRsc is calculated according to semi-quantitative parameter proposed by Old [42] and represents the log2 ratio between the protein expression level of control vs
the protein expression level of NSCLC tissues. Proteins with Rsc ≥ 1,50 or ≤ -1,50 were considered differentially expressed
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volved in LC development, progression and therapy, and
b) the differentially expressed lung proteins between
NSCLC and cancer-free tissues in order to define novel
biomarkers for NSCLC.
Our data confirmed that ERK1/2, AKT, IKBα and NF-
κβ are proteins activated and/or over-expressed in
NSCLC. RAS–ERK has, until now, been one of the most
extensively studied signaling pathways as ERK1/2 path-
way being often up‐regulated in different human tumors
and therefore represents an attractive target for the de-
velopment of anticancer drugs. Although the activation
status of ERK1/2 has been largely studied in various cell
lines, few previous reports have demonstrated an aber-
rant activation of ERK1/2 in human tumors especially in
that of lung [27, 28]. In this study, we identified an over-
phosphorylation of ERK1/2 in NSCLC confirming this
kinase as a key molecular component implicated also in
NSCLC cancer.
PI3K/AKT kinase pathway is another central regulator
of cell metabolism, proliferation, and survival [29–33].
Furthermore, AKT is activated in pre-neoplastic and
neoplastic lesions and has been linked to ineffectiveness
of therapies resulting in poor prognosis [29, 30]. Inparticular, activation of PI3K/AKT pathway in NSCLC
has been associated with increased cellular survival and
resistance to chemotherapy and radiation, two important
clinical problems encountered in several cancers [29].
Our data showed an over-activation of AKT in NSCLC
cancer specimens. We analyzed not only AKT, but also
the expression of IKBα and NF-kβ, other components
connected to the PI3K/AKT pathway and involved in
the control of survival and inflammation. The over-
activation/expression of these molecules strongly sup-
ports that ERK1/2 and AKT pathways as well as IKBα/
NF-κβ axis to be potential biomarkers for diagnosis/
prognosis as well as development of novel targeted drugs
in NSCLC. On the other hand, inactivation of NF-κβ, in
combination with chemotherapeutic agents, leads to bet-
ter therapeutic effects in several cancers [31, 32].
Our investigation also focused on the search for novel
putative LC biomarkers. Proteomics in cancer research
is a technology, by simultaneously examining thousands
of proteins, can lead to the discovery of novel bio-
markers for cancer [33]. We analyzed and compared the
protein expression profile obtained from NSCLC and ad-
jacent cancer-free lung tissues and, through a label-free
proteomic approach, defined a set of 20 differentially
Fig. 4 Western blot analysis confirms CAI and CAII as the two most differentially expressed proteins in NSCLC compared to control tissues. One
representative western blot image (a) and graphical representation of pixel quantization (b) of CAI and CAII in lung tissues from 3 NSCLC patients
(3 with histotype of AC and 1 with histotype of ASC). Each experiment was performed three times in duplicate* = p < 0.05 by t-test analysis. For
other details see materials and methods
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expressed in NSCLC respect to control tissues. To our
knowledge, some of them have been previously correlated
to LC: aldolase A (ALDOA), phosphoglycerate mutase 1
(PGAM1), l-lactate dehydrogenase A isoform 1 (LDHA),
enoyl-CoA hydratase (HADHA), and stomatin (STOM)
[33–37]. Here we report the first experimental evidence of
a significant increase of the above mentioned proteins in
tissues from NSCLC patients. ALDOA, in fact, has been
identified as a differentially expressed protein in the bron-
choalveolar lavage of patients with LC and/or COPD [33].
Our data of PGAM1 over-expression agrees with that pre-
viously found in SCLC and adenocarcinomas (AC) [36].
In addition, LDHA over-expression supports recent find-
ings from NSCLC mouse models both providing a trans-
lational impact to murine data and demonstrating the
key role of LDHA in LC onset and progression [37].
Regarding the over-expression of HADHA protein, a
significant positive correlation between HADHA
expression and LC tumor was observed both in
cisplatin-resistant LC cells and bioptic specimens from
chemotherapy-resistant patients affected by NSCLC, or
SCLC or AC has been reported [34]. As for STOM, our
observation is in contrast with the only other report
describing STOM role in carcinogenesis showing anunder-expression of STOM protein n NSCLC tissues
with positive lymph node metastasis [35].
The two most under-expressed proteins in NSCLC tis-
sues, CAI and CAII, belong to a widespread family of 16
metallo-isoenzymes that catalyze the interconversion be-
tween carbon dioxide and the bicarbonate ion; these en-
zymes are involved in crucial physiological processes
connected to respiration and transport of CO2/bicarbon-
ate, in pH and CO2 homeostasis, and in many other meta-
bolic reactions [38]. Furthermore, reduction of CAs levels
causes CO2 intracellular retention with consequent in-
creased acidification of extracellular pH, a typical condi-
tion observed in rapidly growing tumors [39, 40].
Recently, a differential expression of CA isoenzymes
has been reported in some malignant tumors, and in
particular CAIX has been shown to be prognostic indi-
cator and a potentially important biomarker in the
evaluation of cancer [39–41]. CAIX is constitutively up-
regulated in several cancer types such as lung cancer,
breast cancer etc. and therefore, IHC analysis of its ex-
pression represents a useful tool for cancer detection,
diagnosis and staging in different tissues [41]. CAI and
CAII are significantly less expressed in colorectal tu-
mors, rectal carcinomas and pancreatic tumors, but
over-expressed in nervous system tumors [40]. Recently,
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growth, angiogenesis and survival [41]. To our know-
ledge, only one study has reported reduction of CAI and
CAII expression in LC hypothesizing their role in
tumour cell motility, tumour growth and metastasis for-
mation [38]. Our data about CAI and CAII confirm and
underline the role of these two isoforms in NSCLC and
support a role for them for the first time as biomarkers
for disease diagnosis and/or prognosis able to select pa-
tients for NSCLC therapy.Conclusions
Much effort is being made in the improvement of cancer
detection, diagnosis and therapy by identifying more spe-
cific molecular biomarkers. In this context, we investigated
and confirmed the involvement of ERK1/2, AKT, IKBα and
NF-κβ proteins in NSCLC. Our data supports a role for
these proteins as targets for development of novel drugs in
LC treatment. Specifically, selective inhibitors of these mo-
lecular pathways could have important clinical implications
for LC treatment. Comparing protein expression profile
between NSCLC and adjacent cancer-free lung tissue,
through a label-free proteomic approach, we found 20 dif-
ferentially expressed proteins; among these we considered
and validated CAI and CAII isoforms, the two most
under-expressed proteins in cancer tissues. Our data
strongly supports a role for these isoenzymes in the diag-
nosis and/or prognosis of NSCLC disease.Highlights
1. ERK1/2, AKT and IKBα/NF-κβ pathways are
significantly over-activated in NSCLC tissues vs con-
trol [p < 0.05].
2. Proteomic analysis revealed 20 differently expressed
proteins (7 under- and 13 over-expressed) between
NSCLC and cancer-free lung tissues (≥1.50 Rsc ≤
−1.50).
3. Carbonic anhydrase I and II isoforms are strongly
over-expressed in NSCLC tissues vs control (p < 0.05).
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